Rat soluble receptor activator of nuclear factor-kB ligand,sRANKL ELISA Kit

Code CSB-E05126r
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name tumor necrosis factor (ligand) superfamily, member 11
Alternative Names Tnfsf11 ELISA Kit; Opgl ELISA Kit; Rankl ELISA Kit; Trance ELISA Kit; Tumor necrosis factor ligand superfamily member 11 ELISA Kit; Osteoclast differentiation factor ELISA Kit; ODF ELISA Kit; Osteoprotegerin ligand ELISA Kit; OPGL ELISA Kit; Receptor activator of nuclear factor kappa-B ligand ELISA Kit; RANKL ELISA Kit; TNF-related activation-induced cytokine ELISA Kit; TRANCE ELISA Kit; CD antigen CD254) [Cleaved into: Tumor necrosis factor ligand superfamily member 11 ELISA Kit; membrane form; Tumor necrosis factor ligand superfamily member 11 ELISA Kit; soluble form] ELISA Kit
Abbreviation TNFSF11
Uniprot No. Q9ESE2
Species Rattus norvegicus (Rat)
Sample Types serum, plasma, cell culture supernates
Detection Range 62.5 pg/mL-4000 pg/mL
Sensitivity 15.6 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cardiovascular
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of rat sRANKL in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:1Average %95
Range %89-101
1:2Average %96
Range %91-105
1:4Average %97
Range %93-102
1:8Average %94
Range %90-99
The recovery of rat sRANKL spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9489-100
EDTA plasma (n=4)10096-103
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
40001.934 1.829 1.882 1.719
20001.194 1.139 1.167 1.004
10000.753 0.733 0.743 0.580
5000.548 0.538 0.543 0.380
2500.385 0.375 0.380 0.217
1250.304 0.294 0.299 0.136
62.50.241 0.237 0.239 0.076
00.163 0.162 0.163  
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days


Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. Induces osteoclastogenesis by activating multiple signaling pathways in osteoclast precursor cells, chief among which is induction of long lasting oscillations in the intracellular concentration of Ca (2+) resulting in the activation of NFATC1, which translocates to the nucleus and induces osteoclast-specific gene transcription to allow differentiation of osteoclasts. During osteoclast differentiation, in a TMEM64 and ATP2A2-dependent manner induces activation of CREB1 and mitochondrial ROS generation necessary for proper osteoclast generation.
Gene References into Functions
  1. results of this study concluded that the RANK, RANK-L and OPG system participates in bone remodeling after RME PMID: 29297549
  2. in this animal model the increase of RANK/RANKL and HGF markers is related to a specific immune response, and probably contributed to the evolution of periodontal disease PMID: 29211121
  3. In the supplemented and nonsupplemented rats groups, RANKL was upregulated compared with the control group. PMID: 28473060
  4. the canonical Wnt pathway inhibitor DKK1 blocked the osteogenesis effect and rescued the ratio of RANKL/OPG in periodontal ligament stem cells under force treatment for 1h PMID: 27154288
  5. study identified a number of differentially expressed bone-related mRNAs of potential significance and confirmed the osteoprotegerin/receptor activator of nuclear factor kappa-B (RANK)/RANK ligand (RANKL) pathway PMID: 25406873
  6. High-dose diosgenin treatment down-regulated expression of RANKL significantly in tibia from OVX rats compared to control. PMID: 25257532
  7. Data indicate that after loading jump (JL) for 6 weeks, the expressions of of interleukin 6 (IL-6), and ligand of receptor activator of NF-kappaB (RANKL) genes were markedly elevated in tibia. PMID: 25200151
  8. mechanical stimulation inhibits the activity of RANKL in rats PMID: 23553492
  9. Our findings indicate that the expression of RANKL in the occlusal portion of the bony crypt is unrelated to osteoclast recruitment and differentiation but is crucial to their activation during the creation of the eruption pathway. PMID: 23636419
  10. RANK and RANKL were expressed by T lymphocytes and macrophages in acute cellular kidney rejection after transplantation in rats PMID: 23769040
  11. In rheumatoid arthritis methotrexate/leflunomide combination therapy would relive the synovium hypertrophy through depressing cell viability and osteoclasia through decreasing RANKL and Il-17. PMID: 23334376
  12. There was no change in OPN expression after orthodontic retention and bone remodeling. PMID: 22353912
  13. the increase in RANK-RANKL expression is a response to podocyte injury, and RANK-RANKL may be a novel receptor-ligand complex for the survival response during podocyte injury. PMID: 22848465
  14. Insulin could promote osteoblastic differentiation of calcifying vascular smooth muscle cells by increased RANKL expression through ERK1/2 activation, but not PI3K/Akt activation. PMID: 22194983
  15. TRANCE/RANKL is constituively expressed by rat plasmacytoid dendritic cells. PMID: 22428075
  16. Pressure-overloaded myocardium generates RANKL, which induces inflammation mediators and myocardial inflammation. PMID: 22298642
  17. Bone loss and recovery in a receptor activator for nuclear factor kappa B ligand (RANKL)-administered rat model was assessed PMID: 20480144
  18. RANKL/OPG are key factors linking bone formation to resorption during bone remodeling. PMID: 21771583
  19. Vitamin C deficiency increased osteoclastogenesis by increasing RANK expression. PMID: 20444587
  20. These results suggest that antibody to RANKL can inhibit A. actinomycetemcomitans-specific T cell-induced periodontal bone resorption by blockade and reduction of tissue sRANKL. PMID: 21078845
  21. RANKL contributes to vascular calcification by regulating bone morphogenetic protein-2 and calcification inhibitor matrix Gla protein (MGP) expression, as well as bone-related proteins, and is counteracted by estrogen in a receptor-dependent manner. PMID: 20595654
  22. the toothless (tl) osteopetrotic rat mutation is not in the TNFSF11 locus PMID: 11804028
  23. accelerates nuclear translocation of nuclear factor kappa B in osteoclasts by elevaing cytosolic Ca2+ PMID: 12496256
  24. Effects of 12-O-tetradecanoylphorbol-13-acetate on osteoclastogenesis and its role in RANKL-induced signaling. PMID: 14672351
  25. RANK ligand is strongly up-regulated during acute heart allograft rejection; its blockade prolongs rat heart allograft survival. PMID: 14734743
  26. Detection of RANKL mRNA and protein in bone cells. PMID: 15704000
  27. Results suggest that the RANKL expressed in thymic epithelial cells plays a role in the development of T cells during thymic regeneration. PMID: 15844004
  28. Portasystemic shunting caused low turnover osteoporosis that was RANKL independent. PMID: 16874862
  29. Prolactin decreased RANKL mrna in cultured osteoblasts. PMID: 18432284
  30. These data indicate that serum 25-hydroxyvitamin D levels are a major determinant of osteoclastogenesis and bone mineral volume. PMID: 18597628
  31. Recombinant RANKL (rRANKL) mutants within the TNF-like core domain exhibited diminished osteoclastogenic potential as compared with wild-type rRANKL1 encoding the full TNF-like core domain [amino acids (aa) 160-318]. PMID: 19008464
  32. Orchiectomy increases the concentration of free sRANKL in bone marrow of aged rats. PMID: 19501680
  33. Bony spur formation can thus be considered a process that occurs independent of TNFalpha and RANKL and is triggered by destructive arthritis. PMID: 19714640

Show More

Hide All

Subcellular Location Cell membrane, Single-pass type II membrane protein, SUBCELLULAR LOCATION: Tumor necrosis factor ligand superfamily member 11, soluble form: Secreted
Protein Families Tumor necrosis factor family
Tissue Specificity Highly expressed in thymus and bone tissues.
Database Links

KEGG: rno:117516

STRING: 10116.ENSRNOP00000013210

UniGene: Rn.217570


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1